--:--:--
⬤ LOW 18 Nov 2026, 14:51 UTC

GSK Marks Second Lung Cancer Drug Approval This Year

On Tuesday, the Food and Drug Administration granted accelerated approval to GSK Plc.’s (NYSE:GSK) Nelkarmi (neladalkib) for locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The milestone marks the second lung cancer approval this year for the European drug giant. Regulators cleared the kinase inhibitor for patients who previously received either one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib or two or more prior ALK TKIs alongside platinum-based chemotherapy in the unresectable locally advanced or metastatic setting. Read Also: GSK’s Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat Clinical Trial Results Show Durable Responses The FDA based its decision on the Phase 1/2 ALKOVE-1 trial, which demonstrated clinically meaningful and durable responses in pretreated patients. Investigators evaluated efficacy in the study across two patient groups to assess confirmed overall response rate (CRR) and duration of response (DOR). Among 67 patients who previously received one ALK TKI consisting of alectinib in the metastatic setting, neladalkib achieved a 49% ORR. Within that responding group, 76% maintained a DOR of at least six months, and 52% maintained a DOR of at least 12 months. Among 155 patients who previously received two or more ALK TKIs and platinum-based chemotherapy, treatment produced a 32% ORR. Of those responders, 69% achieved a DOR of at least six months, while 51% reached a DOR of at least 12 months. GSK added the drug via a Nuvalent deal worth $10.6 billion. The acquisition gives GSK three lung cancer assets in a single transaction, including Nuvalent’s lead drug candidates, zidesamtinib and neladalkib, which are being developed for certain forms of non-small cell lung cancer. GSK Price Action: Gsk shares were up 0.12% at $49.30 at the time of publication on Wednesday, according to Benzinga Pro data. Read Also: ‘Steve Jobs Ruined Everything With the iPhone:' Palmer Luckey Blames Apple’s Simplified Design for Killing the Art of Mastering Technology Photo via Shutterstock
\
Terms of Service